IQVIA SOLUTIONS ASIA PTE. LTD.
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Computer Processing and Data Preparation and Processing Services, Information Retrieval Services), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about IQVIA SOLUTIONS ASIA PTE. LTD.
Live alerts from global media, monitored by Business Radar
2025-05-06 (santelog.com)
Supernus Announces First Quarter 2025 Financial Results |
First quarter 2025 net sales of Qelbree ® increased 44% to $64.7 million, compared to the same period in 2024.
Read more
2025-05-05 (fiercepharma.com)
US net drug spending surged 11.4% last year, boosted by obesity and oncology meds: IQVIA |
As sure as the sun rises, prescription medicine use and total drug spending continue to increase in the U.S. | Last year's $50 billion increase in net drug spending marked a period of "historic growth" that was only surpassed by 2021's COVID-19 vaccine launches, according to a new report from life sciences intelligence firm IQVIA.
Read more
2025-04-25 (lifesciencereport.com)
Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance -
Reiterates 2025 guidance of LINZESS U.S. net sales of $800-$850 million and total Ironwood revenue of $260-290 million LINZESS (Iinaclotide) EUTRx ...
Read more
2025-04-06 (marketbeat.com)
2Xideas AG Has $44.30 Million Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)
2Xideas AG lifted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 14.5% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 225,423 shares of the medical research company's stock after buying an
Read more
2025-03-06 (manilatimes.net)
SCIENTURE to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P. |
TAMPA, FL, March 06, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce that its wholly owned subsidiary, Scienture, LLC ("Scienture"), has entered into a definitive agreement with SUMMIT BIOSCIENCES INC. (a wholly owned subsidiary of Kindeva Drug Delivery L.P. ("Kindeva")), for the exclusive U.S. rights to commercially launch REZENOPY® (naloxone HCl) Nasal Spray 10mg, an opioid antagonist that was approved by the FDA on April 19, 2024.
Read more
2025-03-06 (docdocdoc.co.kr)
Rogue Foam, Korea's general drug hair loss treatment market is the No. 1 market <Pharmaceutical · Bio <Industry <Article
Johnson & Johnson's sales company (Kenview) Korea announced on the 5th that the hair loss treatment 'Loin Foam' recorded annual sales of 10.7 billion won in 2024, ranking No. 1 in the domestic drug hair loss treatment market. It was ranked No. 1 in the treatment market. It has surpassed 10 billion won in annual sales seven years after its launch in 2017. The Login Foam is an improvement product of the minoxidil brand 'Login', which was first approved by the US Food and Drug Administration (FDA) in 1988, and changed the liquid type to a form (bubble) type.
Read more
2025-02-27 (stocktitan.net)
Ironwood Pharmaceuticals Announces 50% Workforce Reduction Amid Mixed 2024 Financial Results | IRWD Stock News
Ironwood reports $351.4M revenue with strategic reorganization expected to save $55-60M annually, despite 15% decrease in LINZESS sales to $916.3M.
Read more
2025-02-07 (sharewise.com)
Iqvia Stock: Q4 Growth Signals Strong 2025 Outlook
Iqvia demonstrated robust performance in the fourth quarter of 2024, with revenue climbing 2.3% year-over-year to reach $3.96 billion. The company's Technology & Analytics Solutions segment emerged
Read more
2025-02-06 (businesswire.com)
IQVIA Reports Fourth-Quarter and Full-Year 2024 Results; Reaffirms Full-Year 2025 Guidance
IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the lif...
Read more
2025-01-29 (marketbeat.com)
Smith Group Asset Management LLC Acquires New Holdings in IQVIA Holdings Inc. (NYSE:IQV)
Smith Group Asset Management LLC acquired a new stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 8,224 shares of the medical research company's stock, valued at app
Read more
2025-01-22 (biospace.com)
IQVIA to Announce Fourth-Quarter and Full-Year 2024 Results on February 6, 2025 -
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its fourth-quarter and full-year 2024 financial results before the market opens on Thursday, February 6, 2025. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com.
Read more
2025-01-05 (marketbeat.com)
Everence Capital Management Inc. Sells 2,778 Shares of IQVIA Holdings Inc. (NYSE:IQV)
Everence Capital Management Inc. lowered its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 48.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 2,920 shares of the medical research company's stock after selling 2,778 shares during th
Read more